Bifogade filer
Press Release (PDF)
Kurs
-7,55%
Likviditet
7,23 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-11-05 | 08:30 | Kvartalsrapport 2026-Q3 |
| 2026-08-20 | 08:30 | Kvartalsrapport 2026-Q2 |
| 2026-05-08 | N/A | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2026-05-07 | N/A | Årsstämma |
| 2026-04-29 | 08:30 | Kvartalsrapport 2026-Q1 |
| 2026-02-18 | - | Bokslutskommuniké 2025 |
| 2026-01-14 | - | Extra Bolagsstämma 2026 |
| 2025-11-06 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-21 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-08 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2025-05-07 | - | Årsstämma |
| 2025-04-29 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-18 | - | Bokslutskommuniké 2024 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-08 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2024-05-07 | - | Årsstämma |
| 2024-04-30 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-12-01 | - | Extra Bolagsstämma 2024 |
| 2023-10-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2023-05-24 | - | Årsstämma |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-11-03 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2022-05-05 | - | Årsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-15 | - | Bokslutskommuniké 2021 |
| 2021-11-03 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2021-05-05 | - | Årsstämma |
| 2021-04-28 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-11 | - | Extra Bolagsstämma 2021 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2021-01-13 | - | Extra Bolagsstämma 2020 |
| 2020-11-10 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-06 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2020-05-05 | - | Årsstämma |
| 2020-05-05 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-11-27 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-28 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-10 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2019-05-09 | - | Årsstämma |
| 2019-05-03 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-10-26 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-25 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-04 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2018-05-03 | - | Årsstämma |
| 2018-04-27 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-14 | - | Bokslutskommuniké 2017 |
| 2017-10-26 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-04 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2017-05-03 | - | Årsstämma |
| 2017-04-28 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-08 | - | Kapitalmarknadsdag 2017 |
| 2017-02-17 | - | Bokslutskommuniké 2016 |
| 2017-02-02 | - | Extra Bolagsstämma 2017 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-17 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-04 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2016-05-03 | - | Årsstämma |
| 2016-04-28 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-11-20 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-20 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-06 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2015-05-05 | - | Årsstämma |
| 2015-05-05 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-27 | - | Bokslutskommuniké 2014 |
| 2014-11-20 | - | Extra Bolagsstämma 2014 |
| 2014-11-20 | - | Kvartalsrapport 2014-Q3 |
| 2014-10-16 | - | Kapitalmarknadsdag 2014 |
| 2014-08-21 | - | Analytiker möte 2014 |
| 2014-08-21 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-09 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2014-05-08 | - | Årsstämma |
| 2014-05-08 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-24 | - | Bokslutskommuniké 2013 |
| 2013-11-21 | - | Kvartalsrapport 2013-Q3 |
| 2013-10-10 | - | Kapitalmarknadsdag 2013 |
| 2013-08-22 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-07 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2013-05-06 | - | Årsstämma |
| 2013-05-06 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-13 | - | 15-7 2013 |
| 2013-02-22 | - | Bokslutskommuniké 2012 |
| 2012-11-20 | - | Kvartalsrapport 2012-Q3 |
| 2012-11-19 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-23 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-11 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2012-05-10 | - | Årsstämma |
| 2012-05-10 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-22 | - | Bokslutskommuniké 2011 |
| 2011-11-15 | - | Kapitalmarknadsdag 2011 |
| 2011-10-24 | - | Kvartalsrapport 2011-Q3 |
| 2011-07-08 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-06 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2011-05-05 | - | Extra Bolagsstämma 2011 |
| 2011-05-05 | - | Årsstämma |
| 2011-05-05 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-22 | - | Bokslutskommuniké 2010 |
| 2010-10-22 | - | Kvartalsrapport 2010-Q3 |
| 2010-07-08 | - | Kvartalsrapport 2010-Q2 |
| 2010-04-30 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2010-04-29 | - | Kvartalsrapport 2010-Q1 |
| 2010-02-18 | - | Bokslutskommuniké 2009 |
| 2009-10-21 | - | Kvartalsrapport 2009-Q3 |
| 2009-07-09 | - | Kvartalsrapport 2009-Q2 |
| 2009-04-24 | - | X-dag ordinarie utdelning MVIR 0.00 SEK |
| 2009-04-23 | - | Årsstämma |
| 2009-04-23 | - | Kvartalsrapport 2009-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative medical treatments in areas of high unmet medical need, announced today that Patrik Norgren has been recruited as CFO and will assume his role on March 23. The timing ensures a smooth transition and effective handover from the outgoing CFO, Magnus Christensen.
- Jens Lindberg, CEO of Medivir: “I would like to extend my sincere thanks to Magnus for his dedicated and great work as CFO over the past over the past 7 years, including taking on the interim CEO role during 2021. I am now pleased to announce that Patrik Norgren has been appointed as our new CFO and will assume his position shortly. With his extensive experience, Patrik will play a key role in supporting our ongoing transformation and in creating long-term value for our shareholders.”
- “I am thrilled to join Medivir at such an exciting stage. With a strengthened ownership base, a strong financial position and groundbreaking projects progressing in clinical development, I look forward to working closely with Jens and the team to create long-term value for our shareholders,” says Patrik Norgren, incoming CFO of Medivir.
Patrik Norgren most recently served as CFO of the Swedish pharmaceutical company Cinclus Pharma. He brings more than 20 years of extensive experience in CFO and senior financial leadership roles across both private and publicly listed companies. Patrik holds a Master of Science in Business and Economics, specializing in Accounting and Auditing, from Luleå University of Technology (Luleå Tekniska Universitet).
For additional information, please contact;
Jens Lindberg
Chief Executive Officer
Medivir AB
Phone: +46 8 5468 3100
Email: jens.lindberg@medivir.com
About Medivir
Medivir develops innovative therapies targeting areas of high unmet medical need. Its drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Medivir’s two lead programs are fostrox, a precision chemotherapy designed to selectively target liver cancer cells while minimizing side effects, and MIV-711, aimed at treating Osteogenesis Imperfecta (brittle bone disease). Both candidates have blockbuster potential, representing significant value creation opportunities for Medivir’s shareholders and affected patients. Collaborations and partnerships play a key role in Medivir’s business model, with drug development conducted either in-house or in partnership. Medivir (Nasdaq Stockholm: MVIR) is listed on the Small Cap segment of Nasdaq Stockholm. More information is available at www.medivir.com
Attachments
Press Release (PDF)